Literature DB >> 22562052

SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury.

Ling-Min Li1, Lei Chen, Guo-Hong Deng, Wen-Ting Tan, Yun-Jie Dan, Rong-Quan Wang, Wen-Sheng Chen.   

Abstract

The organic anion transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1) plays an important role in the transport of endogenous and xenobiotic compounds, such as bile acids and rifampin. In this study, the association between OATP1B1 polymorphisms and rifampin hepatotoxicity was investigated using integrated population genetic analysis and functional studies. A total of 273 unrelated patients treated with rifampin were recruited. The allele frequencies were examined in patients with drug (rifampin)-induced liver injury (DILI) (n = 118) and without (non-DILI) (n = 155). Functional analyses were conducted to determine whether the inhibition of bile acids by rifampin was associated with OATP1B1 variants. In the present study, 24 single nucleotide polymorphisms (SNPs) in OATP1B1 were detected in a Chinese population, with two of them causing an amino acid change (rs2306283 and rs4149056). The haplotypes constructed by these two SNPs were OATP1B1 *1a, *1b, *5 and *15, with their respective frequencies being 23.44, 66.30, 0.73 and 9.52% in a total of 273 individuals. The logistic regression analysis indicated that the *15 haplotype was associated with susceptibility to DILI (p = 0.03, OR = 2.04, 95% CI 1.05-3.96). The frequency of the *15 haplotype in DILI patients was significantly higher than that in non-DILI patients (p = 0.03). In the subgroup analysis, the *15 haplotype was associated with susceptibility to cholestatic/mixed injury (p = 0.03, OR = 2.31, 95% CI 1.06-5.02). Functional assessment of the OATP1B1 *15 haplotype revealed that the activity of bile acid uptake was markedly reduced compared to the three other haplotypes. In the inhibition study, the inhibition by rifampin in the *15 haplotype was greater compared to that in the other haplotypes. These results suggest that the OATP1B1 *15 haplotype is an important predisposing factor for rifampin-induced liver injury.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22562052     DOI: 10.3892/mmr.2012.900

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  14 in total

1.  Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers.

Authors:  Yao Chen; Wei Zhang; Wei-hua Huang; Zhi-rong Tan; Yi-cheng Wang; Xi Huang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2013-07-07       Impact factor: 2.953

2.  Genomewide Association Study Confirming the Association of NAT2 with Susceptibility to Antituberculosis Drug-Induced Liver Injury in Thai Patients.

Authors:  Supharat Suvichapanich; Sukanya Wattanapokayakit; Taisei Mushiroda; Hideki Yanai; Charoen Chuchottawon; Tassawan Kantima; Supalert Nedsuwan; Wimon Suwankesawong; Cholticha Sonsupap; Roongkarn Pannarunothai; Sukanya Tumpattanakul; Warawut Bamrungram; Achara Chaiwong; Surakameth Mahasirimongkol; Sasithorn Mameechai; Weerapat Panthong; Nantawan Klungtes; Amara Munsoo; Udomrat Chauychana; Molrudee Maneerat; Koya Fukunaga; Yosuke Omae; Katsushi Tokunaga
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Microcystin-LR induced liver injury in mice and in primary human hepatocytes is caused by oncotic necrosis.

Authors:  Benjamin L Woolbright; C David Williams; Hongmin Ni; Sean C Kumer; Timothy Schmitt; Bartholomew Kane; Hartmut Jaeschke
Journal:  Toxicon       Date:  2016-11-23       Impact factor: 3.033

4.  Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.

Authors:  Zelalem Petros; Eyasu Makonnen; Eleni Aklillu
Journal:  OMICS       Date:  2017-02-16

5.  NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis.

Authors:  M Richardson; J Kirkham; K Dwan; D J Sloan; G Davies; A L Jorgensen
Journal:  Int J Tuberc Lung Dis       Date:  2019-03-01       Impact factor: 2.373

6.  Impact of SLCO1B1*5 on Flucloxacillin and Co-Amoxiclav-Related Liver Injury.

Authors:  Mohammad Alshabeeb; Fadhel A Alomar; Amjad Khan
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

Review 7.  MicroRNAs in Drug-induced Liver Injury.

Authors:  Li-Min Li; Dong Wang; Ke Zen
Journal:  J Clin Transl Hepatol       Date:  2014-09-15

8.  Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol).

Authors:  Marty Richardson; Jamie Kirkham; Kerry Dwan; Derek Sloan; Geraint Davies; Andrea Jorgensen
Journal:  Syst Rev       Date:  2017-07-13

9.  Rifampicin Transport by OATP1B1 Variants.

Authors:  Carlijn H C Litjens; Jeroen J M W van den Heuvel; Frans G M Russel; Rob E Aarnoutse; Lindsey H M Te Brake; Jan B Koenderink
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

10.  Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations.

Authors:  Agnes Nagy; Csilla Sipeky; Renata Szalai; Bela Imre Melegh; Petra Matyas; Alma Ganczer; Kalman Toth; Bela Melegh
Journal:  BMC Genet       Date:  2015-09-03       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.